Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Evaluation of the GenoType® MTBDR sl assay in Korean patients with MDR or XDR tuberculosis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Subject Terms:
    • Abstract:
      BackgroundThis study used the GenoType® MTBDRslassay (MTBDRsl, Hain Lifescience, Nehren, Germany), an assay for anti-tuberculosis drug susceptibility testing, for the detection of resistance of 40 tuberculosis strains to fluroquinolones (FLQ), injectable drugs (amikacin or capreomycin) and ethambutol to identify multi-drug resistant and extensively drug-resistant tuberculosis patients previously identified by solid drug susceptibility test (DST).MethodsThese tuberculosis strains were analysed by both DNA sequencing and conventional drug susceptibility testing on solid medium.ResultsThe overall agreement rates of the MTBDRslassay and phenotypic drug susceptibility testing for the detection of ofloxacin (OXF), moxifloxacin (MXF), amikacin (AMK), capreomycin (CPM) and ethambutol (EMB) susceptibility in clinical strains were 87.5% (35/40), 87.5% (35/40), 97.5% (39/40), 60.0% (24/40) and 65.0% (26/40), respectively.ConclusionsThis study reconfirmed 37 extensively drug-resistant tuberculosis strains using the MTBDRslassay and these strains were verified by phenotypic drug susceptibility testing. After identification with the MTBDRslassay, the results were analysed by DNA sequencing with specific primers. From the various mutations identified in the DNA sequencing results, this study found new mutations that characterised EMB-resistant strains, namely, R507K and G406T mutations, which had not been previously reported. [ABSTRACT FROM AUTHOR]